A case-control study found that GROa (CXCL1) is overexpressed in the brains of 23 Alzheimer’s disease patients, with no prior diagnosis of immunological diseases, hypertension, cardiac disease or diabetes, compared to age-matched controls (Zhang et al., 2013). Here, CXCL1 is linked to early-onset autosomal dominant Alzheimer disease.